Inhibition of FAS/FAS-ligand does not block chemotherapy-induced apoptosis in drug sensitive and resistant cells

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 259-266

  Richardson, Deborah S ^a,b   Allen, Paul D ^a   Kelsey, Stephen M ^a   Newland, Adrian C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; FASLG PROTEIN, HUMAN; FLUDARABINE; IDARUBICIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; VIDARABINE; VINBLASTINE;

APOPTOSIS; ARTICLE; CELL CLONE; CELL CULTURE; CELL CYCLE; CELL STRAIN HL 60; DRUG EFFECT; HUMAN; IMMUNOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; T CELL LEUKEMIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CLONE CELLS; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; FAS LIGAND PROTEIN; HL-60 CELLS; HUMANS; IDARUBICIN; LEUKEMIA, T-CELL, ACUTE; MEMBRANE GLYCOPROTEINS; TUMOR CELLS, CULTURED; VIDARABINE; VINBLASTINE;

EID: 0032611146     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_28     Document Type: Article

References (23)

1. Dive C, Wyllie AH. Apoptosis and cancer chemotherapy. In: Hickman JA, Tritton TR, eds. Cancer Chemotherapy. Oxford: Blackwell Scientific Publications; 1993:21-55.
2. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer. 1991, 64,192-196.
3. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poIy(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993, 53(17),3976-85.
4. Nagata S. Apoptosis by death factor. Cell. 1997, 88,355-365.
5. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO, Stricker K, Bäumler C, Hellbardt S, Germer M, Peter ME, Debatin K-M. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 1994, 142,175-191.
6. Schlegel J, Peters I, Orrenius S, Miller DK, Thornberry NA, Yamin TT, Nicholson DW. CPP32/apopain is a key interleukin l beta converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem. 1996, 271(4). 1841-4.
7. Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H, Tsujimoto Y. Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis. Cancer Res. 1996, 56(8), 1713-8.
8. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (fas/APO-l)-mediated T cell apoptosis. J Exp Med. 1996, 184,765-770.
9. Debatin K-M, Goldmann CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal antibody-mediated apoptosis in adult T-cell leukaemia. Lancet. 1990,335,497-500.
10. Debatin K-M, Goldmann CK, Waldmann TA, Krammer PH. APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood. 1993, 81,2972-2977.
11. Nonomura N, Miki T, Yokoyama M, Imazu T, Takada T, Takeuchi S, Kanno N, Nishimura K, Kojima Y, Okuyama A. Fas/APO-l-mediated apoptosis of human renal cell carcinoma. Biochem Biophys Res Commun. 1996,229,945-951.
12. Friesen C, Herr l. Kramer PH, Debatin K-M. Involvement of the CD95 (APO-1/Fas) receptor/1igand system in drug-induced apoptosis in leukemia cells. Nature Med. 1996,2,574-577.
13. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 1979,39(6),2070-6.
14. Kartner N, Riordan JR, Ling V. Cell surface p-glycoprotein is associated with multidrug resistance in mammalian cell lines. Science. 1983,221,1285-8.
15. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992, 13,795-808.
16. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997, 99(3),403-13.
17. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-l/CD95) ligand expression but occurs independently of Fas (Apo-l/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 1997, 57(16),333l-4.
18. Tewari M, Dixit M. Fas- and tumour necrosis factor-induced apoptosis is inhibited by the cowpox virus crmA gene product. J Biol Chem. 1995, 270,3255-3260.
19. Gamen S, Anel A, Lasierra P, Alava MA, Martinezlorenzo MJ, Pineiro A, Naval J. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a fas-independent way. FEBS Lett. 1997, 417(3),360-364.
20. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997, 90(3),935-43.
21. Dirks W, Schöne S, Uphoff C, Quentmeier H, Pradella S, Drexler HG. Expression and function of CD95 (fas/apo-1 ) in leukaemia-lymphoma tumour lines. Br J Haematol. 1997, 96,584-593.
22. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA. 1985, 82,790-794.
23. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to fas-mediated apoptosis. Blood. 1997, 89(6), 1854-1861.